Want to see FR:BOI full AI Analyst Report?
BOI Stock Chart & Stats
€27.30
-€0.50(-1.83%)
At close: 4:00 PM EDT
€27.30
-€0.50(-1.83%)
Day’s Range― - ―
52-Week Range€20.85 - €32.25
Previous CloseN/A
Volume2.80K
Average Volume (3M)4.19K
Market Cap
€480.01M
Enterprise Value€344.59
Total Cash (Recent Filing)€79.34M
Total Debt (Recent Filing)€31.48M
Price to Earnings (P/E)14.7
Beta0.15
Next Earnings
Sep 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.93%
Share Statistics
EPS (TTM)1.86
Shares Outstanding17,545,408
10 Day Avg. Volume1,557
30 Day Avg. Volume4,187
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.35
Price to Sales (P/S)1.06
P/FCF Ratio17.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.06
Revenue Forecast (FY)€522.30M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageBoiron’s very low debt-to-equity profile provides lasting financial flexibility. Low leverage supports capacity to fund operations, sustain dividend policy and weather demand shocks without heavy refinancing, preserving strategic optionality across 2–6 months and beyond.
Positive Cash GenerationConsistent positive operating cash flow demonstrates core cash-generating ability from consumer OTC sales. Even with some volatility, recurring OCF underpins reinvestment, working-capital needs and shareholder returns, supporting the firm’s operating model over the medium term.
Improved ProfitabilityMargins and ROE recovery indicate better operating leverage and pricing/mix execution. A sustained net margin near mid-single digits and improving ROE support durable internal funding and demonstrate the business can restore profitability after prior weaknesses.
Bears Say
Severe 2025 Revenue DropA pronounced 2025 revenue contraction materially reduces visibility into future top-line trends. For a consumer-health company reliant on repeat pharmacy sales, such contractions can erode shelf presence, weaken distributor relationships and constrain medium-term growth prospects.
Volatile Free Cash FlowMarked swings in free cash flow undermine predictability for dividends, share buybacks and reinvestment. Even with positive OCF overall, sharp year-to-year FCF declines can force prioritization of liquidity over strategic investments, weakening longer-term reinvestment capacity.
Shrinking Equity BaseDeclining equity and asset levels reduce the firm’s capital buffer and may limit balance-sheet flexibility. A smaller capital base constrains the ability to finance expansion, absorb shocks or pursue acquisitions, increasing structural risk if top-line weakness persists.
BOI FAQ
What was Boiron SA’s price range in the past 12 months?
Boiron SA lowest stock price was €20.85 and its highest was €32.25 in the past 12 months.
What is Boiron SA’s market cap?
Boiron SA’s market cap is €480.01M.
When is Boiron SA’s upcoming earnings report date?
Boiron SA’s upcoming earnings report date is Sep 09, 2026 which is in 35 days.
How were Boiron SA’s earnings last quarter?
Boiron SA released its earnings results on Mar 18, 2026. The company reported €1.206 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Boiron SA overvalued?
According to Wall Street analysts Boiron SA’s price is currently Overvalued.
Does Boiron SA pay dividends?
Boiron SA pays a Annually dividend of €1.35 which represents an annual dividend yield of 4.93%. See more information on Boiron SA dividends here
What is Boiron SA’s EPS estimate?
Boiron SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boiron SA have?
Boiron SA has 17,545,408 shares outstanding.
What happened to Boiron SA’s price movement after its last earnings report?
Boiron SA reported an EPS of €1.206 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.58%.
Which hedge fund is a major shareholder of Boiron SA?
Currently, no hedge funds are holding shares in FR:BOI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boiron SA
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.